Manganese for Blood Sugar and Glucose Metabolism
Manganese sits at the metabolic crossroads of glucose homeostasis. Two of the body's most important gluconeogenic enzymes — pyruvate carboxylase (the first committed step of gluconeogenesis) and phosphoenolpyruvate carboxykinase (PEPCK) — are manganese-dependent. Experimental manganese deficiency in rodents produces measurable abnormalities in glucose tolerance and insulin response. A Chinese case-control study found a U-shaped association between blood plasma manganese and type 2 diabetes — both low and high plasma levels went with higher odds — while studies of manganese in the diet found that people eating more manganese developed type 2 diabetes less often. Manganese also interacts with magnesium in glucose homeostasis: both minerals share transport routes, both are required for adenosine triphosphate-magnesium complex function in glucose phosphorylation, and combined deficiency produces synergistic dysregulation. While manganese is not a treatment for diabetes, adequate manganese status is one of the foundational nutritional requirements for normal glucose metabolism.
Table of Contents
- Why Glucose Metabolism Needs Manganese
- Pyruvate Carboxylase: The Gluconeogenic Entry Point
- Phosphoenolpyruvate Carboxykinase (PEPCK)
- TCA Cycle Anaplerosis and Glucose-Alanine Cycling
- Manganese Deficiency and Impaired Insulin Response
- Glucose Tolerance: Human Studies and Animal Models
- The Manganese-Magnesium Interplay in Glucose Homeostasis
- Type 2 Diabetes: U-Shaped Risk Curve
- MnSOD and Diabetic Complications
- Key Facts for People with Blood-Sugar Problems
- Key Research Papers
- Connections
- Featured Videos
Why Glucose Metabolism Needs Manganese
Glucose homeostasis is the body's most carefully regulated metabolic parameter. Plasma glucose must be maintained within a narrow range (approximately 70-110 mg/dL in the fasting state) because both hypoglycemia (impaired brain function) and hyperglycemia (vascular and tissue damage) are immediately dangerous. The regulatory system has three principal components: dietary glucose absorption, hepatic glucose production (gluconeogenesis and glycogenolysis), and peripheral glucose uptake (especially by muscle and adipose tissue under insulin control).
Manganese is critical at two specific points in this system:
- Hepatic glucose production via gluconeogenesis — the synthesis of new glucose from non-carbohydrate precursors (lactate, amino acids, glycerol) during fasting, prolonged exercise, or low-carbohydrate states. Two of the four uniquely gluconeogenic enzymes — pyruvate carboxylase and PEPCK — require manganese.
- TCA cycle anaplerosis — replenishment of TCA cycle intermediates that are drawn off for biosynthesis. Pyruvate carboxylase is the principal anaplerotic enzyme, generating oxaloacetate from pyruvate.
The integration of these two roles places manganese directly in the path of glucose-handling in fasting metabolism. Inadequate manganese status compromises both gluconeogenesis (impaired generation of new glucose when needed) and TCA cycle function (impaired oxidative adenosine triphosphate (ATP) production from carbohydrate, fat, and protein substrates).
Pyruvate Carboxylase: The Gluconeogenic Entry Point
Pyruvate carboxylase (PC, EC 6.4.1.1) catalyzes the adenosine triphosphate-dependent carboxylation of pyruvate to oxaloacetate:
Pyruvate + CO2 + adenosine triphosphate → Oxaloacetate + ADP + Pi
This is the first committed step of gluconeogenesis from pyruvate or lactate, and it is also the principal anaplerotic reaction that replenishes oxaloacetate for TCA cycle function. The enzyme is a biotin-dependent carboxylase with a complex active-site architecture that includes both a biotin cofactor and a manganese ion (or, in some species and tissues, magnesium — the two divalent metals can substitute to some extent, but manganese has higher catalytic efficiency).
- Tissue distribution — PC is highly expressed in liver, kidney cortex, and adipose tissue (where it supports fatty acid synthesis by providing oxaloacetate for citrate export from mitochondria). The liver and renal cortex are the principal sites of physiologic gluconeogenesis.
- Regulation — PC is allosterically activated by acetyl-CoA. This creates an elegant control logic: when fatty acid oxidation is high (generating abundant acetyl-CoA), PC is activated to generate oxaloacetate, which the liver uses for gluconeogenesis during the fasting state.
- Inherited PC deficiency — a rare autosomal recessive disorder causing severe lactic acidosis, hypoglycemia, hyperammonemia, and severe neurological impairment. The phenotype demonstrates how dependent the body is on this single enzyme for both glucose synthesis and TCA cycle integrity.
- Manganese vs magnesium at the active site — in vitro, both metals can support catalysis. In vivo, the strict requirement for manganese has been debated, with some authors arguing the enzyme is functionally a magnesium-enzyme in mammals. However, manganese deficiency consistently reduces PC activity in animal models, suggesting that even if magnesium can substitute, manganese is the preferred and physiologically dominant cofactor.
Phosphoenolpyruvate Carboxykinase (PEPCK)
PEPCK (EC 4.1.1.32) is the second committed enzyme of gluconeogenesis. It catalyzes the GTP-dependent decarboxylation and phosphorylation of oxaloacetate to phosphoenolpyruvate (PEP):
Oxaloacetate + GTP → PEP + CO2 + GDP
This reaction effectively reverses the pyruvate kinase step of glycolysis (which generates pyruvate from PEP). The combined PC + PEPCK pathway converts pyruvate to PEP, bypassing the irreversible pyruvate kinase reaction and committing carbon to the gluconeogenic direction.
- Manganese cofactor — PEPCK is strictly metal-dependent for activity, with manganese as the highest-activity cofactor. Magnesium can substitute with reduced efficiency. The metal participates in the GTP-mediated phosphoryl transfer chemistry.
- Cytosolic vs mitochondrial isoforms — humans express two PEPCK genes: PCK1 (cytosolic, PEPCK-C) and PCK2 (mitochondrial, PEPCK-M). Both are manganese-dependent and both contribute to gluconeogenesis in different proportions in different tissues. PEPCK-C dominates in liver and kidney; PEPCK-M has been increasingly recognized as important in many cancers and in islet beta-cell function.
- Transcriptional regulation — PEPCK-C transcription is upregulated by glucagon, cortisol, and starvation, and downregulated by insulin and feeding. This transcriptional control is part of how insulin suppresses hepatic glucose output. Resistance to this suppression (insulin resistance in type 2 diabetes) leads to inappropriately high hepatic gluconeogenesis even in the fed state — one of the central pathologies of the disease.
- Therapeutic target — metformin (the first-line type 2 diabetes drug) reduces hepatic glucose output in part by inhibiting mitochondrial gluconeogenic flux, which has effects on PEPCK function. The fact that the most successful diabetes drug works in part through this pathway underscores its physiologic importance.
TCA Cycle Anaplerosis and Glucose-Alanine Cycling
The tricarboxylic acid (TCA) cycle generates reduced nicotinamide adenine dinucleotide (NADH) and FADH2 for the electron transport chain and supplies precursors for biosynthesis: alpha-ketoglutarate for amino acid synthesis, succinyl-CoA for heme synthesis, oxaloacetate for gluconeogenesis and aspartate synthesis. When TCA intermediates are drawn off for biosynthesis (cataplerosis), they must be replaced (anaplerosis) or the cycle will run down.
Pyruvate carboxylase is the dominant anaplerotic enzyme in most mammalian tissues. Inadequate manganese reduces PC activity, slows anaplerosis, and gradually depletes TCA cycle intermediates. The result is reduced oxidative adenosine triphosphate production from all substrates (glucose, fatty acids, amino acids) and increased reliance on glycolytic (anaerobic) adenosine triphosphate production with lactate accumulation. This metabolic shift mimics in miniature what happens in more severe mitochondrial disorders.
The glucose-alanine cycle is one specific case where manganese's role is particularly visible. Working muscle generates alanine (from pyruvate by transamination with glutamate), which is exported to the liver. In the liver, alanine is converted back to pyruvate (with the amino group destined for the urea cycle, which itself requires manganese-containing arginase). Pyruvate then enters gluconeogenesis via manganese-dependent PC and PEPCK to regenerate glucose, which returns to the muscle. Manganese is required at two steps of this cycle (arginase in urea synthesis, PC and PEPCK in gluconeogenesis) plus one nitrogen-disposal step (glutamine synthetase in skeletal muscle for ammonia handling).
Manganese Deficiency and Impaired Insulin Response
Classical experimental manganese deficiency studies (rodents, guinea pigs) report that manganese deprivation impairs glucose handling and the insulin response. The one controlled human depletion study reports no glucose result in its published summary:
- Friedman et al. (1987), the controlled human depletion study — seven young men aged 19-22 ate a purified diet supplying only 0.11 mg of manganese a day for 39 days. Blood cholesterol fell (from 170 to 152 mg/dL during the normal-food baseline weeks, then to 142 mg/dL by the end of depletion), and five of the seven men developed a short-lived skin rash (miliaria crystallina) that faded as manganese was restored. The minimum manganese requirement calculated from this study was 0.74 mg/day.
- Rodent oral glucose tolerance studies — manganese-deficient rats consistently show flattened insulin response curves and elevated post-load glucose. The defect is partially reversible with manganese repletion within days to weeks.
- Islet beta-cell function — pancreatic beta cells express both MnSOD and the gluconeogenic enzymes that are manganese-dependent. Reduced manganese availability impairs glucose-stimulated insulin secretion in vitro, possibly through effects on intracellular adenosine triphosphate production and the K-ATP channel mechanism that triggers insulin release.
- Insulin signaling and oxidative stress — oxidative stress contributes to insulin resistance through multiple mechanisms (serine phosphorylation of IRS-1, JNK activation, NF-kB activation). Reduced MnSOD activity, by allowing greater mitochondrial oxidative stress, may indirectly worsen insulin sensitivity.
- Hepatic insulin signaling — the liver's response to insulin involves suppression of gluconeogenic gene expression (FOXO1, PEPCK, glucose-6-phosphatase). The transcriptional response is normal in manganese deficiency, but the impact on the metabolic flux is altered because the enzymes are partially inactive at the protein level.
Glucose Tolerance: Human Studies and Animal Models
The human glucose-tolerance literature on manganese is limited and mixed:
- Walter et al. (1991) — compared 57 people with insulin-dependent or non-insulin-dependent diabetes from a university diabetes clinic with 28 people without diabetes and found no difference in whole-blood manganese. The differences it did find were higher plasma copper, lower plasma zinc, and more zinc and magnesium lost in the urine in the diabetic group.
- Koh et al. (2014) — a cross-sectional study of 3,996 Korean adults from the national health and nutrition survey found lower blood manganese in people with diabetes than in people without it (1.26 vs 1.35 µg/dL). Diabetes was present in 7.6% of people in the lowest quarter of blood manganese against 5.3% in the higher three quarters (adjusted odds ratio 0.652 for the higher quarters, 95% CI 0.46-0.92).
- Du et al. (2018) — two prospective cohorts of Chinese adults (3,350 and 7,133 people, followed for an average of 4.2 and 5.3 years) found that people eating more manganese developed type 2 diabetes less often and had lower HbA1c (a blood test of average blood sugar over about three months). Average intake was about 4.6 mg/day; intakes above about 6 mg/day (over 6.01 and 6.10-6.97 mg/day in the two cohorts) went with significantly lower diabetes incidence, and the link was stronger in diets high in antioxidants.
- Animal studies — consistently show that manganese-deficient animals have impaired glucose tolerance and reduced insulin response. The defect appears at multiple points: reduced beta-cell insulin secretion, impaired peripheral glucose uptake, and dysregulated hepatic glucose output.
- Manganese repletion in deficient individuals — restoration of normal dietary manganese normalizes glucose handling in deficient animals.
- What is not known — the human findings above are cross-sectional and cohort associations: they show that manganese and blood sugar travel together, not that one causes the other. None of these studies tested manganese supplements, and none shows that manganese supplements change blood sugar.
The Manganese-Magnesium Interplay in Glucose Homeostasis
Magnesium and manganese have overlapping roles in glucose metabolism, and their statuses are nutritionally interrelated. Understanding the interplay helps clarify why neither mineral acts in isolation.
- Shared substrate, partial substitution — many enzymes that use one divalent metal will accept the other with reduced efficiency. Pyruvate carboxylase, PEPCK, and most kinases that nominally use Mg-ATP can use Mn-ATP. In tissues with adequate manganese, partial substitution at magnesium-preferring enzymes may explain some clinical signals.
- Glucose phosphorylation — hexokinase and glucokinase use Mg-ATP as substrate (more accurately, the magnesium-ATP complex). Magnesium is rate-limiting; manganese substitution is possible but slower.
- Insulin receptor tyrosine kinase — the insulin receptor's intracellular tyrosine kinase activity is magnesium-dependent. Low intracellular magnesium impairs insulin signal transduction and contributes to insulin resistance.
- Combined deficiency — in chronic conditions associated with combined magnesium and manganese deficiency (chronic alcoholism, severe protein-calorie malnutrition, post-bariatric surgery), the impact on glucose homeostasis exceeds what either deficiency alone would produce.
- Transport competition — divalent metal transporter 1 (DMT1) handles iron, manganese, and other divalent cations. High iron supplementation can reduce manganese uptake and indirectly affect magnesium-manganese balance. The ZIP14 transporter handles manganese, zinc, and iron. The overlapping transport network means trace-mineral status is best assessed as a panel rather than as individual minerals.
- Evidence balance — for people with blood-sugar problems, adequate magnesium intake (300-400 mg/day) has stronger evidence behind it than manganese supplementation. Manganese has an adult Tolerable Upper Intake Level of 11 mg/day from all sources.
For more on magnesium and glucose metabolism, see the Magnesium page.
Type 2 Diabetes: U-Shaped Risk Curve
One of the more interesting findings in nutritional epidemiology of manganese is the U-shaped relationship between blood manganese and type 2 diabetes reported by Shan et al. (2016). In a Chinese case-control study of 3,228 people (1,614 with newly diagnosed type 2 diabetes and 1,614 without), the odds of diabetes were higher at both low and high plasma manganese — odds ratio 1.89 for the lowest third and 1.56 for the highest third, compared with the middle third — with the lowest odds at a plasma manganese of about 4.95 µg/L. Studies of manganese in the diet have found a falling, not U-shaped, risk (see below). Proposed reasons why both very low and very high manganese could matter:
- Low manganese — impaired gluconeogenic enzyme function, reduced beta-cell capacity, increased oxidative stress in beta cells and peripheral tissues
- High manganese — possibly pro-oxidant effects of free manganese, manganese-induced mitochondrial dysfunction, displacement of magnesium and other divalent metals from regulatory sites, oxidative stress paradoxes at very high concentrations
- Where the lowest risk sat — in the Shan study, the lowest odds were in the middle third of plasma manganese (around 4.95 µg/L). In the two Chinese diet cohorts (Du et al., 2018), the lowest diabetes incidence went with intakes above about 6 mg/day, below the adult Tolerable Upper Intake Level (UL) of 11 mg/day; the adult Adequate Intake (AI) is 1.8-2.3 mg/day
A 2026 study pooled six long-term cohorts with more than 270,000 people: each extra 1 mg of manganese a day from food went with about 4% lower risk of type 2 diabetes (pooled relative risk 0.96, 95% CI 0.94-0.99), in a curved rather than straight-line pattern. In its own UK Biobank part (165,194 people), the highest-intake fifth did not have a significantly lower risk than the lowest fifth (hazard ratio 0.91, 95% CI 0.82-1.01), and heart and blood-vessel disease risk was unchanged (hazard ratio 0.99) (Gebretsadik et al., 2026).
None of these studies tested high-dose manganese supplements. A varied diet with whole grains, nuts, legumes, leafy greens, and tea typically supplies the Adequate Intake without supplements.
The U-shape also has an environmental-exposure component — populations with high environmental manganese (well water above EPA limits, certain industrial regions) may have elevated diabetes risk that masquerades as a "high-intake" effect but is really an inhalational or non-physiologic exposure problem.
MnSOD and Diabetic Complications
Once type 2 diabetes is established, mitochondrial superoxide overproduction in target tissues (vascular endothelium, retinal capillaries, renal tubular cells, peripheral nerves) is the upstream driver of the major chronic complications. The Brownlee unifying hypothesis places mitochondrial superoxide at the apex of the complication cascade:
- Hyperglycemia accelerates flux through the electron transport chain in target tissues
- Excess electron flow generates excess superoxide at complexes I and III
- If MnSOD capacity is exceeded, superoxide accumulates
- Superoxide activates four damaging downstream pathways (polyol, hexosamine, PKC, advanced glycation end-product formation)
- The four pathways converge on vascular and neuronal damage manifesting as nephropathy, retinopathy, neuropathy, and accelerated atherosclerosis
MnSOD adequacy is therefore upstream of the entire complication cascade. The SOD2 Val16Ala polymorphism (discussed in detail on the antioxidant MnSOD deep-dive) modulates this. In lab studies, the Val form of the enzyme gets into the mitochondria less well: the Ala form produced 30-40% more of the active enzyme than the Val form (Sutton et al., 2003). In a Danish study of people with type 1 diabetes (441 with diabetic kidney disease and 314 without it after at least 20 years of diabetes), carriers of the Val allele (Val/Val or Val/Ala) had more diabetic kidney disease (odds ratio 1.7, 95% CI 1.2-2.4) and more cardiovascular disease during follow-up (hazard ratio 1.6, 95% CI 1.0-2.5), independent of HbA1c (Möllsten et al., 2009).
This does not mean manganese supplementation prevents diabetic complications — the evidence does not support that claim. It means manganese adequacy is one of multiple inputs to a system that, when working well, buffers the diabetic state and slows complication onset.
Key Facts for People with Blood-Sugar Problems
- Dietary adequacy — the adult Adequate Intake is 1.8-2.3 mg/day from food sources. Whole grains, nuts, legumes, leafy greens, tea, and pineapple are the major contributors. A varied diet supplies this without difficulty.
- Upper limit — the Institute of Medicine Tolerable Upper Intake Level for adults is 11 mg/day from all sources combined. None of the studies on this page tested manganese supplements for blood sugar.
- Magnesium evidence — for blood-sugar problems specifically, magnesium has a stronger evidence base than manganese. 300-400 mg/day of magnesium (from food and/or supplement) improves insulin sensitivity in deficient individuals. Magnesium glycinate and magnesium malate are forms commonly described as well tolerated.
- The broader nutritional picture — zinc, chromium, biotin, vitamin D, omega-3 fatty acids, B vitamins (especially thiamine, B6, folate, B12) all have roles in glucose metabolism. Single-mineral approaches are less effective than comprehensive nutritional optimization.
- Lifestyle remains primary — even with optimal micronutrient status, glycemic dysregulation in the type 2 diabetes spectrum responds primarily to dietary carbohydrate moderation, regular aerobic and resistance exercise, adequate sleep, stress management, and weight management. Micronutrient support is adjunctive, not curative.
- Special populations — patients with chronic alcoholism, post-bariatric surgery, inflammatory bowel disease, celiac disease, and long-term parenteral nutrition are at risk of multi-mineral deficiency including manganese. Comprehensive trace-mineral assessment and repletion is part of standard management.
- Liver disease caution — patients with cirrhosis or biliary obstruction cannot excrete manganese normally and are at risk of manganese building up in the central nervous system (CNS); for this group the research raises a concern about any manganese beyond what food supplies.
This content is provided for informational purposes only and does not constitute medical advice. Nutrition is one component of diabetes care, alongside medicines, physical activity and blood-sugar monitoring.
Key Research Papers
- Friedman BJ, Freeland-Graves JH, Bales CW, et al. (1987). Manganese balance and clinical observations in young men fed a manganese-deficient diet. Journal of Nutrition 117(1):133-143. — PubMed PMID: 3819860
- Brownlee M (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615-1625. — PubMed PMID: 15919781
- Koh ES, Kim SJ, Yoon HE, et al. (2014). Association of blood manganese level with diabetes and renal dysfunction: a cross-sectional study of the Korean general population. BMC Endocrine Disorders 14:24. — PubMed PMID: 24606630
- Du S, Wu X, Han T, et al. (2018). Dietary manganese and type 2 diabetes mellitus: two prospective cohort studies in China. Diabetologia 61(9):1985-1995. — PubMed PMID: 29971528
- Shan Z, Chen S, Sun T, et al. (2016). U-shaped association between plasma manganese levels and type 2 diabetes. Environmental Health Perspectives 124(12):1876-1881. — PubMed PMID: 27258818
- Gebretsadik GG, Yang B, Glenn AJ, et al. (2026). Dietary manganese, type 2 diabetes, and cardiovascular disease: a UK Biobank cohort study and meta-analysis of over 270,000 individuals. Journal of Nutrition, Health and Aging 30(2):100754. — PubMed PMID: 41380425
- Jomova K, Valko M (2011). Advances in metal-induced oxidative stress and human disease. Toxicology 283(2-3):65-87. — PubMed PMID: 21414382
- Burch HB et al. (1975). Hereditary pyruvate carboxylase deficiency: leigh-like syndrome and metabolic acidosis. Journal of Pediatrics. — PubMed
- Sutton A, Khoury H, Prip-Buus C, et al. (2003). The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13(3):145-157. — PubMed PMID: 12618592
- Möllsten A, Jorsal A, Lajer M, Vionnet N, Tarnow L (2009). The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in type 1 diabetes. Diabetologia 52(12):2590-2593. — PubMed PMID: 19834686
- Walter RM et al. (1991). Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. Diabetes Care 14(11):1050-1056. — PubMed PMID: 1797486
- Burrage LC et al. (2014). Disorders of branched chain amino acid metabolism: from rare leucine, isoleucine, and valine cycles to MSUD treatment paradigms. Human Molecular Genetics. — PubMed
- Rorsman P, Ashcroft FM (2018). Pancreatic beta-cell electrical activity and insulin secretion: of mice and men. Physiological Reviews 98(1):117-214. — PubMed PMID: 29212789
PubMed Topic Searches
Connections
- All Minerals
- Manganese Overview
- Manganese Benefits Hub
- Manganese for Bone Formation
- Manganese MnSOD Antioxidant
- Manganese for Wound Healing
- Magnesium
- Chromium
- Zinc
- Vitamin D3
- Type 2 Diabetes
- Metabolic Syndrome
- Obesity
- Insulin Resistance
- Oxidative Stress
- Brown Rice
- Spinach
- Cinnamon
- Deficiency
- Toxicity
- History
- Sources